title: Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
authors: Jean Philippe
authors: JP
authors: Arnault
authors: Janine
authors: J
authors: Wechsler
authors: Bernard
authors: B
authors: Escudier
authors: Alain
authors: A
authors: Spatz
authors: Gorana
authors: G
authors: Tomasic
authors: Vincent
authors: V
authors: Sibaud
authors: Selim
authors: S
authors: Aractingi
authors: Jean-Didier
authors: JD
authors: Grange
authors: Vichnou
authors: V
authors: Poirier-Colame
authors: David
authors: D
authors: Malka
authors: Jean-Charles
authors: JC
authors: Soria
authors: Christine
authors: C
authors: Mateus
authors: Caroline
authors: C
authors: Robert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015603:Keratinocytes / Q000473:pathology*; D007636:Keratoacanthoma / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D000077157:Sorafenib; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib